HRMY — AI Stock Analysis & Recommendation

TradeFlare's AI research teams rate HRMY a BUY. The current price is $37.03.

• Entry: $39.57
• Target: $45.5
• Stop: $33.63

The fundamental strength and positive sentiment suggest a medium-term upward trend, but technicals and risk warrant a cautious approach. Catalysts to watch: Continued strong performance of WAKIX, driving revenue and earnings growth; Positive analyst sentiment and increasing price targets; Potential pipeline advancements and regulatory updates. Key risks: Heavy reliance on WAKIX for revenue (concentration risk); Significant historical drawdown and high-volatility nature of the stock; Insider selling by the Chief Medical Officer.

Last updated October 14, 2026 · AI-generated analysis for informational purposes, not financial advice.